Influencia del sexo en el tratamiento con olanzapinauna revisión sistemática

  1. Susana Alberich
  2. Mónica Martínez-Cengotitabengoa
  3. Itxaso González-Ortega
  4. Jessica Fernández-Sevillano
  5. Judith Usall
  6. Ana González-Pinto
Revue:
Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica

ISSN: 1134-5934

Année de publication: 2019

Volumen: 26

Número: 2

Pages: 45-51

Type: Article

DOI: 10.1016/J.PSIQ.2019.06.001 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica

Objectifs de Développement Durable

Résumé

Olanzapine is an antipsychotic drug commonly used in the treatment of illnesses such as schizophrenia and bipolar disorder. Occasionally the manifestation of the illness differs between genders, but little has been investigated on the influence of this biological difference in the response to the treatment or the secondary effects. In this systematic review, an analysis is made of these gender differences on the effectiveness and adverse effects of olanzapine treatment. Although some studies showed a higher effectiveness in women, this was ambiguous due to not finding any differences in other works. On the other hand, there was a greater tendency for men to gain weight and suffer from Parkinson symptoms, while the women were more likely to suffer from dizzy spells, a greater increase in cholesterol, and in QT interval. Given the worldwide use of olanzapine, it is important that further studies should be performed to analyse these differences observed, since they could be crucial for improving the quality of life of the patients.